Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

TTVR Remains Safe, Effective in Presence of CIED Leads

News Conference News TCT 2025

TTVR Remains Safe, Effective in Presence of CIED Leads

October 25, 2025

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

News Conference News TCT 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

Michael O'Riordan

October 29, 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

News Conference News TCT 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

October 27, 2024

Watchman, Amulet LAAO Devices Have Similar Leak Rates at About 1 Year

News Conference News TCT 2023

Watchman, Amulet LAAO Devices Have Similar Leak Rates at About 1 Year

October 25, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

News Conference News TCT 2021

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

November 06, 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

November 05, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

Pacemaker-Based Approach Tricks the Body Into Lower BP: MODERATO II

News Conference News TCT 2019

Pacemaker-Based Approach Tricks the Body Into Lower BP: MODERATO II

October 09, 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

News Conference News TCT 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

October 04, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

September 19, 2019

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

September 17, 2018

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

November 09, 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

November 08, 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

November 02, 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.